Section Arrow
IMVT.NASDAQ
- Immunovant
Quotes are at least 15-min delayed:2026/09/04 07:44 EDT
Pre Market
Last
 39.25
+0.13 (+0.33%)
Bid
38.6
Ask
39.75
High 39.7 
Low 38.6 
Volume 240 
Regular Hours (Closed)
Last
 39.12
-0.37 (-0.94%)
Day High 
39.48 
Prev. Close
39.49 
1-M High
45.42 
Volume 
1.24M 
Bid
38.6
Ask
39.75
Day Low
38.64 
Open
39.48 
1-M Low
36.78 
Market Cap 
8.16B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 42.47 
20-SMA 42.22 
50-SMA 40.4 
52-W High 45.42 
52-W Low 14.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.81/-2.85
Enterprise Value
8.16B
Balance Sheet
Book Value Per Share
3.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
Pre Market 15.38 +0.53 +3.57%
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
Pre Market 0.2328 -0.0009 -0.39%
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
Pre Market 7.34 0 0.00%
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
Pre Market 17 -0.13 -0.76%
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Pre Market 8.77 +0.07 +0.80%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.